10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Sunday, June 6, 2010

Granules India Ltd:-Buy/sell/hold,growth prospects and recomendation,news and results,target price and analysis,views and outlook

Scripscan:Granules India Ltd
Bse code:532482
Percentage return:20%
Duration:4-6 months

Story:-Granules India operates on a strong and sustainable business model with the unique concept of manufacturing single and combinational pharmaceutical formulation ingredients, PFIs, the directly compressible granules for use in generic drugs which provides cost advantage to outsourcing players with reduced regulatory hassles.The company is set to enhance margins by focusing on value added product mix by emphasizing more on high margin and high volume products. The firm has forward integrated into finished dosages and dossier fillings and it has also backward integrated by creating additional capacities for some strategic active pharmaceutical ingredients, APIs like Naproxen and Aspirin. GIL has alsocommissioned in Sept 08 a state of the art tableting facility with a capacity of 6 Billion tablets.Which is scalable to 12 billion tablets with minimal investment.Its main focus is to provide an outsourcing platform for OTC and Rx to OTC drug marketers by positioning itself as a strong value added service provider across the value chain.As the company moves into higher value added prescription PFI and tableting revenues,I believe the company would get re-rated. Higher CAGR revenue growth of 50%+ for the next two years and CAGR profit growth of 75% for the next two years would re-rate the company.Granules has always been into the radar of several big investors but never really performed on the bourses as such.With robust numbers set to come quarter after quarter, I feel shareholders would have a gala time with these counter going forward.A solid buy at current levels.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner